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Introduction. Nicotinic acid (NA) and statins have been associated with reductions in blood pressure (BP). Patients and Methods.
We recruited 68 normotensive and hypertensive dyslipidemic patients who were treated with a conventional statin dose and had
not achieved lipid targets. Patients were randomized to switch to high-dose rosuvastatin (40mg/day) or to add-on current statin
treatment with extended release (ER) NA/laropiprant (1000/20mg/day for the ﬁrst 4 weeks followed by 2000/40mg/day for the
n e x t8w e e k s )f o r3m o n t h s .Results. Switching to rosuvastatin 40mg/day was not associated with signiﬁcant BP alterations. In
contrast, the addition of ER-NA/laropiprant to current statin treatment resulted in a 7% reduction of systolic BP (from 134±12 to
125 ±10mmHg, P<. 001 versus baseline and P = .01 versus rosuvastatin group) and a 5% reduction of diastolic BP (from 81 ±9
to 77 ± 6mmHg, P = .009 versus baseline and P = .01 versus rosuvastatin group). These reductions were signiﬁcant only in the
subgroup of hypertensives and were independent of the hypolipidemic eﬀects of ER-NA/laropiprant. Conclusions.C o n t r a ryt ot h e
switch to high-dose rosuvastatin, the addition of ER-NA/laropiprant to statin treatment was associated with signiﬁcant reductions
in both systolic and diastolic BP.
1.Introduction
Hypertension and dyslipidemia, two powerful risk factors
for cardiovascular disease, often coexist, and their combined
eﬀect is much greater than the sum of their individual eﬀects
[1]. Moreover, a growing body of evidence supports that
dyslipidemia may predate the onset of hypertension, while a
genetic link between dyslipidemia and hypertension cannot
be excluded [2, 3]. Statins, the mainstay of lipid-lowering
therapy,resultinasigniﬁcantclinicalbeneﬁtbothinprimary
and secondary cardiovascular prevention [4]. In addition
to their hypolipidemic capacity, other properties may con-
tribute to statin-induced beneﬁts, including a reduction of
blood pressure (BP) [5–9]. In this context, rosuvastatin has
been associated with reductions in BP and BP variability in
animal studies [6, 10].
Nicotinic acid (NA) comprises the oldest hypolipidemic
drug in use since 1955, and it has been associated with
BP decrease in a number of studies [11, 12]. Recently, the
European Medicine Agency approved a ﬁxed combination of
extended release (ER) NA with laropiprant (a prostaglandin
D2 receptor antagonist) which reduces NA-induced ﬂushing
without altering the beneﬁcial eﬀects of NA on lipid proﬁle
or BP [13–15].
We aimed to compare the possible BP eﬀects of switching
to high-dose rosuvastatin with add-on-current statin ER-
NA/laropiprant in normotensive and hypertensive patients
with primary dyslipidemia who were currently treated with
a conventional statin regimen but had not achieved the
treatment goals. To our best of knowledge, such comparison
has not been made before. Secondary endpoints included
changes in lipid proﬁle.2 International Journal of Hypertension
2. Patientsand Methods
2.1. Study Population. Consecutive subjects with primary
hypercholesterolemia (n = 70) attending the Outpatient
Lipid and Obesity Clinic of the University Hospital of
Ioannina, Ioannina, Greece were recruited. Eligible patients
were those treated for at least 3 months with a conventional
statin dose (10–40mg simvastatin or 10–20mg atorvastatin
or 5–20mg rosuvastatin) and their low-density lipoprotein
cholesterol (LDL-C) or non-high-density lipoprotein choles-
terol (non-HDL-C) levels were above those recommended
by the National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP-ATP) III based on each patient risk
factors [16].
Subjects with triglycerides (TG) >500mg/dL (5.65
mmol/L), renal disease (serum creatinine levels >1.6mg/dL,
141μmol/L), hypothyroidism (thyroid stimulating hormone
(TSH) >5IU/mL), and liver disease (alanine aminotrans-
ferase (ALT) and/or aspartate aminotransferase (AST) levels
>3-fold upper limit of normal in 2 consecutive mea-
surements) were excluded from the study. Patients with
hypertension and/or diabetes were considered eligible if they
were on stable medication for at least 3months and their
BP and/or glycemic proﬁle were adequately controlled (no
change in their treatment was allowed during study period).
Patients were randomly allocated (without a washout
phase) to open-label high-dose rosuvastatin (40mg/day) or
to add-on current statin treatment with ER-NA/laropiprant
(1000/20mg/day for the ﬁrst 4weeks, followed by 2000/40
mg/day for the next 8weeks) for a total of 3months.
All patients were given similar dietary advice. Compli-
ance with treatment and lifestyle habits was assessed by
questionnaire and tablet count. All study participants gave
their written informed consent prior to enrolment, and the
Ethics Committee of the University Hospital of Ioannina
approved the study protocol.
2.2. Laboratory Measurements. Visits took place at baseline
and 12weeks after the start of treatment. At each visit, BP
was measured in triplicate in the right arm after patients
hadrestedfor10minutesinasittingposition.Measurements
were performed by trained clinicians using an electronic
sphygmomanometer (WatchBP Oﬃce, Microlife WatchBP
AG, Widnau, Switzerland).
Blood samples for laboratory tests were obtained after a
12h overnight fast. Levels of total cholesterol (TC), HDL-
C, and triglycerides (TG) were determined enzymatically
in the laboratory of the University Hospital of Ioannina
using an Olympus AU 600 analyzer (Olympus Diagnos-
tica GmbH, Hamburg, Germany). LDL-C was calculated
using the Friedewald equation (provided that TGs were
<350mg/dL (3.95mmol/L)). All laboratory determinations
were performed blindly with regard to treatment allocation.
2.3. Statistical Analysis. We used G∗Power 3.0.10 to calculate
sample size. Based on previous studies we estimated that
ER-NA/laropiprant would result in a 3% reduction of BP
[15], while switching to rosuvastatin would not alter BP
since patients were already receiving a statin. Power analysis
revealed that a sample size of 30 patients per group would
give a 99% power to detect diﬀerences between groups at
an α level lower than 0.05. We recruited 68 patients allowing
for a dropout rate of ∼10%. The Kolmogorov-Smirnov test
was used to evaluate whether each parameter followed a
Gaussiandistribution,andlogarithmictransformationswere
accordingly performed. Values are given as mean ± standard
deviation (SD) and median (range) for parametric and
nonparametric data, respectively. The diﬀerences of study
parameters between baseline and posttreatment values were
evaluated by paired sample t-test (or Wilcoxon’s rank test for
non-Gaussian variables). Analysis of covariance (ANCOVA)
adjusted for baseline values was used for the comparisons
between treatment groups. Statistical signiﬁcance was set at
P<. 05. Analyses were performed using SPSS version 15.0
(SPSS Inc., Chicago, Illinois).
3. Results
Recruitment took place from October 2009 to September
2010, and followup ended in December 2010. Initially, 68
Caucasian patients were enrolled. Sixty patients (27 men,
59 ± 11 years) completed the study, since 7 participants in
the ER-NA/laropiprant group dropped out due to ﬂushing
as well as 1 patient in the rosuvastatin group due to ALT
elevation >3-fold upper normal limit. No cases of hypoten-
sion were reported. No diﬀerence in baseline parameters
was found between the 2 groups (Table 1). Compliance rate
was >80% in all participants who completed the study.
No changes in body weight, dietary habits (including salt
intake), or antihypertensive or antidiabetic medications were
reported during the followup.
Intheswitch-to-rosuvastatin40mg/daygroup,nosignif-
icant BP alterations were reported (Table 2). In contrast, the
addition of ER-NA/laropiprant to current statin treatment
resultedinasigniﬁcant7%reductionofsystolicBP(P<. 001
versus baseline and P = .01 versus rosuvastatin 40mg) and
a signiﬁcant 5% reduction of diastolic BP (P = .009 versus
baeline and P = .01 versus rosuvastatin 40mg) (Table 2).
In the subgroup of hypertensive subjects (n = 18)
theadd-on-current-statin ER-NA/laropiprant wasassociated
with a 7% and 6% signiﬁcant reduction of systolic and
diastolic BP, respectively, compared with baseline (systolic
BP from 133 ± 6 to 124 ± 11mmHg, P = .009 and
diastolic BP from 80 ± 9t o7 5± 6mmHg, P = .03). In
normotensive subjects (n = 12) the add-on-current-statin
ER-NA/laropiprant resulted in similar though not signiﬁcant
BP alterations (−6% (from 131 ± 5 to 125 ± 6mmHg) and
-5% (from 83 ± 5t o7 9± 6mmHg), respectively, P = NS
versus baseline and P = NS versus hypertensive subgroup).
Intheswitch-to-rosuvastatin40mggroup,bothhypertensive
and normotensive subjects demonstrated no signiﬁcant BP
alterations (data not shown).
Both the switch to rosuvastatin 40mg and add-on-statin
ER-NA/laropiprant signiﬁcantly decreased TC, LDL-C, TGs
and non-HDL-C compared with baseline (all P<. 001)
(Table 2). The change in LDL-C was more pronounced inInternational Journal of Hypertension 3
Table 1: Baseline characteristics and medications of study partici-








N (females/males) 30 (17/13) 30 (16/14) NS
Age (years) 62 ± 10 58 ± 14 NS
Current smokers (%) 7 (23) 10 (33) NS
Diabetes mellitus (%) 4 (13) 6 (20) NS
Metabolic syndrome (%) 15 (50) 16 (53) NS
Body weight (kg) 79 ± 10 81 ± 10 NS
BMI (kg/m2) 29.1 ± 2.5 29.1 ± 3.1 NS
Waist circumference (cm) 102 ± 89 9 ± 8 NS
SBP (mmHg) 127 ± 14 134 ± 12 NS
DBP (mmHg) 80 ± 78 1 ± 9 NS
Hypertensive subjects (%) 15 (50) 18 (60) NS
TC (mg/dL) 226 ± 36 202 ± 42 NS
(mmol/L) 5.8 ± 0.9 5.2 ± 1.1
Triglycerides (mg/dL) 169 (150–189) 164 (141–187) NS
(mmol/L) 1.9 (1.7–2.1) 1.9 (1.6–2.1)
HDL-C (mg/dL) 55 ± 94 7 ± 11 NS
(mmol/L) 1.4 ± 0.2 1.2 ± 0.3
LDL-C (mg/dL) 142 ± 45 112 ± 35 NS
(mmol/L) 3.7 ± 1.2 2.9 ± 0.9
Non-HDL-C (mg/dL) 175 ± 33 155 ± 37 NS
(mmol/L) 4.5 ± 0.9 4.0 ± 1
Medications at baseline
Aspirin 98 NS
Beta blockers 88 NS
HCTZ 10 11 NS
ACEIs/ARBs 12 14 NS
Calcium channel blockers 79 NS




Atorvastatin 5–20 mg/day 10 9 NS
Simvastatin 10–40 mg/day 13 9 NS
Rosuvastatin 5–20 mg/day 71 2 NS
ER-NA: extended release nicotinic acid, NS: not signiﬁcant, BMI: body
mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure,
TC: total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-
C: low-density lipoprotein cholesterol, HCTZ: hydrochlorothiazide, ACEIs:
angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor
blockers. ∗Values are expressed as mean ± standard deviation (except for
triglycerides which are expressed as median (range)).
the switch-to-rosuvastatin 40mg compared with add-on-
current-statin ER-NA/laropiprant group. In contrast, TGs
and HDL-C levels were improved more with add-on-statin
ER-NA/laropiprant compared with switch-to-rosuvastatin
40mg (Table 2). The observed BP reductions were not
signiﬁcantly correlated with HDL-C increase or other lipid
changesintheadd-on-statinER-NAgroup(datanotshown).
4. Discussion
This is the ﬁrst study to directly compare the antihy-
pertensive potential of switching to high-dose statin with
add-on-current statin ER-NA/laropiprant. We demonstrated
that add-on-current-statin ER-NA/laropiprant but not the
switch to rosuvastatin 40mg is associated with signiﬁcant
reductions of both systolic and diastolic BP in patients
with primary dyslipidemia, especially in the subgroup of
hypertensives.
A growing body of evidence suggests that statins may
reduce BP [5, 8, 9, 17, 18]. The eﬀects of rosuvastatin
on systemic and regional hemodynamics were evaluated
in 2 hypertensive rat models (one genetically determined
and one hypertensive-induced via inhibition of nitric oxide
(NO) synthesis) [7]. Rosuvastatin reduced arterial BP in
hypertensive rats and decreased total peripheral resistance
[7]. Regional hemodynamics improved with rosuvastatin in
both hypertensive models, as evidenced by increased blood
ﬂow and decreased vascular resistance [7]. These eﬀects were
independent of changes in plasma lipids. In addition, rosu-
vastatin has been associated with improved BP variability in
genetically dyslipidemic mice (apolipoprotein E −/−)a n d
reduced systolic BP in obese rats with chronic kidney injury
[6, 19]. Moreover, in obese and dyslipidemic (leptin- and
LDL-receptor-deﬁcient) mice rosuvastatin reduced systolic
BP to the same levels compared with age-matched wild
type control mice despite incomplete correction of insulin
resistance and regardless of dose [10].
The mechanisms by which statin may reduce BP remain
unknown [20]. It is possible that statin eﬀects on BP
are mediated by endothelial function improvement. Of
note, among the pleiotropic actions of rosuvastatin are
the reduction of proinﬂammatory cytokines and endoge-
nous NO synthase inhibitor levels, the promotion of NO
function and peroxisome proliferator-activated receptor
gamma (PPARγ) expression, and the increase of superoxide
dismutase 1 which represent major antioxidants in the
vasculature [6, 7, 10]. Moreover, in a placebo-controlled
study, rosuvastatin (10mg/day) decreased P-selectin in
60 patients with pulmonary arterial hypertension (PAH)
[21]. P-selectin is a crucial player in inﬂammation and
thrombosis, and its reduction by rosuvastatin is relevant to
the pathophysiological scenario of PAH and potentially to
arterialBP[21].Anotherpossiblemechanismisviaincreased
1,25 dihydroxyvitamin D levels [22]. Indeed, a growing
body of evidence suggests that vitamin D may decrease BP
[22, 23].
In our study, the switch to rosuvastatin 40mg/day was
not associated with signiﬁcant BP reductions. A possible
explanation could be that all patients were already receiving
baseline statin treatment. As the BP-lowering eﬀect of
rosuvastatin has been demonstrated to be independent of4 International Journal of Hypertension
Table 2: Clinical and laboratory parameters at baseline and 3months after treatment∗.
Baseline 3months Percentage change (%)
Body weight (kg)
Switch-to-rosuvastatin 40mg 79 ± 10 79 ± 9 0
Add-on-statin ER-NA/laropiprant 81 ± 10 81 ± 10 0
SBP (mmHg)
Switch-to-rosuvastatin 40mg 127 ± 14 127 ± 12 0
Add-on-statin ER-NA/laropiprant 134 ± 12 125 ± 10 −7††,§
DBP (mmHg)
Switch-to-rosuvastatin 40mg 80 ± 77 9 ± 6 −0.1
Add-on-statin ER-NA/laropiprant 81 ± 97 7 ± 6 −5†,§
TC, mg/dL (mmol/L)
Switch-to-rosuvastatin 40mg 226 ± 36 (5.8 ± 0.9) 180 ± 30 (4.7 ± 0.8) −20††
Add-on-statin ER-NA/laropiprant 202 ± 42 (5.2 ± 1.1) 171 ± 37 (4.4 ± 1) −15††
Triglycerides, mg/dL (mmol/L)
Switch-to-rosuvastatin 40mg 169 (150–189) 156 (129–183) −7††
[1.9 (1.7–2.1)] [1.8 (1.5–2.1)]
Add-on-statin ER-NA/laropiprant 164 (141–187) 123 (97–148) −25††,§
[1.9 (1.6–2.1)] [1.4 (1.1–1.7)]
HDL-C, mg/dL (mmol/L)
Switch-to-rosuvastatin 40mg 55 ± 9( 1 . 4± 0.2) 54 ± 9( 1 . 4± 0.2) −0.2
Add-on-statin ER-NA/laropiprant 47 ± 11 (1.2 ± 0.3) 53 ± 16 (1.4 ± 0.4) +13†,§
LDL-C, mg/dL (mmol/L)
Switch-to-rosuvastatin 40mg 142 ± 45 (3.7 ± 1.2) 98 ± 30 (2.5 ± 0.8) −30††,‡
Add-on-statin ER-NA/laropiprant 112 ± 35 (2.9 ± 0.9) 91 ± 34 (2.4 ± 0.9) −19††
Non-HDL-C, mg/dL (mmol/L)
Switch-to-rosuvastatin 40mg 175 ± 33 (4.5 ± 0.9) 127 ± 26 (3.3 ± 0.7) −40††
Add-on-statin ER-NA/laropiprant 155 ± 37 (4.0 ± 1) 118 ± 34 (3.1 ± 0.9) −24††
SBP: systolic blood pressure, DBP: diastolic blood pressure, ER-NA: extended release nicotinic acid, TC: total cholesterol, HDL-C: high-density lipoprotein
cholesterol, LDL-C: low-density lipoprotein cholesterol, non-HDL-C: non-high-density lipoprotein cholesterol.
∗Values are expressed as mean ± standard deviation (except for triglycerides which are expressed as median (range)).
†P<. 01 versus baseline.
††P<. 001 versus baseline.
§P<. 01 versus and switch-to-rosuvastatin 40mg group.
‡P<. 01 versus the add-on-statin ER-NA/laropiprant group.
dose and changes in lipids, at least in animal models, it
is possible that the switch to high-dose rosuvastatin does
not result in any further reduction in BP compared with
preexisting statin treatment [6, 7, 9, 10].
Despite the use of NA for approximately 50 years, there
areonlyfewreportsontheeﬀectsofNAonBP[11,24,25].In
one study NA was intravenously infused to 11 normotensive
a n d1 0h y p e r t e n s i v es u b j e c t s[ 26]. In the normotensives,
systolic, diastolic, and mean BP and pulse pressure were not
aﬀected by NA. In contrast, the hypertensive subjects expe-
rienced a decrease in mean BP from 105 ± 2mmHg to 100
± 3mmHg (P<. 01) accompanied by signiﬁcant decreases
in systolic, diastolic, and pulse pressures.[26] Another study
reached similar results, supporting that NA (500mg/day for
7days and then 1g/day for further 7days) does not have an
acute eﬀe c to nB Pi nn o r m o t e n s i v es u b j e c t s[ 27]. A post-hoc
analysis of the Coronary Drug Project (CDP) demonstrated
that 1-year therapy with NA in patients with metabolic
syndrome was associated with a 2.2mmHg reduction of
systolic BP compared with a rise of 0.8mmHg in the placebo
group(P<. 0001)[28].Additionally,diastolicBPdeclinedby
2.9mmHgcomparedwith0.9mmHgdecreaseintheplacebo
group (P<. 0001) [28]. In a post-hoc analysis of a 24-weeks,
phase 3 trial, 1613 dyslipidemic patients were randomized
in ER-NA alone or ER-NA/laropiprant combination or
placebo [15]. BP decreased with ER-NA, while laropiprantInternational Journal of Hypertension 5
did not attenuate or abolish this eﬀect [15]. Speciﬁcally,
the placebo-adjusted mean changes from baseline in systolic
BP were −2.2 and −3.1mmHg in the ER-NA and ER-
NA/laropiprant groups (P<. 05 and P<. 001, resp.), while
similar changes were reported for diastolic BP (−2.7 and
−2.5mmHg in the ER-NA and ER-NA/laropiprant groups,
respectively, both P<. 001) [15]. Of note, the reduction
of systolic BP in the ER-NA and ER-NA/laropiprant groups
was more pronounced in patients not receiving antihyper-
tensive treatment compared with those on such treatment.
On the contrary, diastolic BP decreased similarly in all
patients receiving ER-NA or ER-NA/laropiprant regardless
of concomitant antihypertensive therapy [15]. There were
also a few cases reported of hypotension (in 0.3%, 0.0%, and
0.7% of patients receiving ER-NA, ER-NA/laropiprant and
placebo, resp.) and orthostatic hypotension (in 0.1%, 0.2%
and 0.0% of patients receiving ER-NA, ER-NA/laropiprant
and placebo, resp.) [15]. In contrast, in a smaller (n = 412)
and shorter study (8weeks), the combination of ER-NA (1-
2g/day) with laropiprant did not signiﬁcantly alter BP levels
[29].
The mechanisms by which NA can reduce BP remain
unknown. Studies with NA and laropiprant suggest that the
latter does not aﬀect BP [15, 30] .T h u s ,i ti su n l i k e l yt h a t
thesechangesaremediatedbyprostaglandinD2 orcutaneous
vasodilatation. Another possible mechanism may be the
improvement in endothelial function, as HDL promotes NO
endothelial generation [31]. Thus, the NA-induced elevation
of HDL may result in a NO-mediated decrease of BP
[31].
In our study, add-on-statin ER-NA/laropiprant was asso-
ciated with signiﬁcant BP reductions, mainly in hypertensive
subjects. The observed BP reductions were not signiﬁcantly
correlated with HDL-C increase or other lipid changes.
Thus, the ER-NA/laropiprant-induced BP lowering may
be independent of lipid changes and may be associated
with the pleiotropic eﬀects of this agent [24]. NA apart
from raising HDL improves several pleiotropic properties
of HDL including improved capacity of HDL to stimulate
endothelial NO, to reduce superoxide production, and to
promote endothelial progenitor cell-mediated endothelial
repair which may be beneﬁcial for endothelial function [32].
Moreover,NAhasbeendirectlyassociatedwiththereduction
of asymmetric dimethylarginine (ADMA), a methylated
amino acid that causes endothelial dysfunction by competi-
tiveinhibitionoftheNOsynthase[33,34].Ofnote,although
ER-NA/laropiprant-associatedBPreductionwasnumerically
similar between normotensives and hypertensives, it was
signiﬁcantonlyinhypertensivesubjects.Thisisinagreement
with a previous study [26]. However, the small number of
patients in the normotensive subgroup does not allow ﬁrm
conclusions.
Both treatments induced favourable changes in lipid
proﬁle. We noticed more pronounced reduction in LDL-C in
the switch-to-rosuvastatin 40mg group compared with the
add-on-statin ER-NA/laropiprant group. As expected, TGs
and HDL-C were improved more with the add-on-statin ER-
NA/laropiprant compared with the switch-to-rosuvastatin
40mg.
5. Study Limitationsand Strengths
A major limitation of our study is its open-label design.
On the other hand, it was an adequately powered random-
ized study that used a validated method for the assessment of
BP. Moreover, all laboratory determinations were performed
blindlywithregardtotreatmentallocation.Thisstudydesign
is relevant to every day clinical practice when the treating
physician is in dilemma over what to do in a patient who
hasfailedtoachievelipidtargetswhileonconventionalstatin
treatment.
Patients with hypertension had adequately controlled BP
readings before study commence. The BP-lowering eﬀect of
NA may be more pronounced in inadequately controlled
hypertensives, but further research in this ﬁeld is needed.
6. Conclusion
The addition of ER-NA/laropiprant to a conventional statin
regimen, but not the switch to high-dose rosuvastatin, is
associated with signiﬁcant reductions of both systolic and
diastolic BP in dyslipidemic patients, especially in those
with hypertension. Addition of ER-NA/laropiprant to a




The authors state no conﬂict of interests and have received
no payment in preparation of this manuscript. Some of
the authors have given talks, attended conferences, and
participated in trials and advisory boards sponsored by
various pharmaceutical companies, including Merck Sharp
and Dohme (MSD).
References
[1] G. K. Goode, J. P. Miller, and A. M. Heagerty, “Hyperlip-
idaemia, hypertension, and coronary heart disease,” Lancet,
vol. 345, no. 8946, pp. 362–364, 1995.
[ 2 ] R .O .H a l p e r i n ,H .D .S e s s o ,J .M a ,J .E .B u r i n g ,M .J .S t a m p f e r ,
and J. M. Gaziano, “Dyslipidemia and the risk of incident
hypertension in men,” Hypertension, vol. 47, no. 1, pp. 45–50,
2006.
[3] R. R. Williams, S. C. Hunt, P. N. Hopkins et al., “Familial
dyslipidemic hypertension. Evidence from 58 Utah families
for a syndrome present in approximately 12% of patients
with essential hypertension,” Journal of the American Medical
Association, vol. 259, no. 24, pp. 3579–3586, 1988.
[4] C.Baigent,L.Blackwell,J .Embersonetal.,“Eﬃcacyandsafety
of more intensive lowering of LDL cholesterol: a meta-analysis
of data from 170,000 participants in 26 randomised trials,”
Lancet, vol. 376, pp. 1670–1681, 2010.
[5] K. E. Ferrier, M. H. Muhlmann, J. P. Baguet et al., “Intensive
cholesterol reduction lowers blood pressure and large artery
stiﬀness in isolated systolic hypertension,” Journal of the
American College of Cardiology, vol. 39, no. 6, pp. 1020–1025,
2002.6 International Journal of Hypertension
[ 6 ]M .P e l a t ,C .D e s s y ,P .M a s s i o n ,J .P .D e s a g e r ,O .F e r o n ,a n dJ .
L. Balligand, “Rosuvastatin decreases caveolin-1 and improves
nitric oxide-dependent heart rate and blood pressure variabil-
ity in apolipoprotein E mice in vivo,” Circulation, vol. 107, no.
19, pp. 2480–2486, 2003.
[7] P. Sicard, S. Delemasure, C. Korandji et al., “Anti-hypertensive
eﬀects of Rosuvastatin are associated with decreased inﬂam-
mation and oxidative stress markers in hypertensive rats,” Free
Radical Research, vol. 42, no. 3, pp. 226–236, 2008.
[8] G. V. Ramesh Prasad, A. Ahmed, M. M. Nash, and J.
S. Zaltzman, “Blood pressure reduction with HMG-COA
reductase inhibitors in renal transplant recipients,” Kidney
International, vol. 63, no. 1, pp. 360–364, 2003.
[ 9 ] L .T e r z o l i ,L .M i r c o l i ,R .R a c o ,a n dA .U .F e r r a r i ,“ L o w e r i n go f
elevated ambulatory blood pressure by HMG-CoA reductase
inhibitors,” Journal of Cardiovascular Pharmacology, vol. 46,
no. 3, pp. 310–315, 2005.
[10] F. Desjardins, B. Sekkali, W. Verreth et al., “Rosuvastatin
increases vascular endothelial PPARγ expression and corrects
blood pressure variability in obese dyslipidaemic mice,”
European Heart Journal, vol. 29, no. 1, pp. 128–137, 2008.
[11] L. A. Carlson, “Nicotinic acid: the broad-spectrum lipid drug.
A 50th anniversary review,” Journal of Internal Medicine, vol.
258, no. 2, pp. 94–114, 2005.
[12] H. E. Bays and D. J. Rader, “Does nicotinic acid (niacin) lower
blood pressure?” International Journal of Clinical Practice, vol.
63, no. 1, pp. 151–159, 2009.
[13] TREDAPTIVE product overview, 2011, http://www.ema
.europa.eu/humandocs/Humans/EPAR/tredaptive/tredaptive
.htm.
[14] D. Maccubbin, H. E. Bays, A. G. Olsson et al.,
“Lipid-modifying eﬃcacy and tolerability of extended-
release niacin/laropiprant in patients with primary
hypercholesterolaemia or mixed dyslipidaemia,” International
Journal of Clinical Practice, vol. 62, no. 12, pp. 1959–1970,
2008.
[15] H. E. Bays, D. Maccubbin, A. G. Meehan, O. Kuznetsova,
Y. B. Mitchel, and J. F. Paolini, “Blood pressure-lowering
eﬀects of extended-release niacin alone and extended-release
niacin/laropiprant combination: a post hoc analysis of a
24-week, placebo-controlled trial in dyslipidemic patients,”
Clinical Therapeutics, vol. 31, no. 1, pp. 115–122, 2009.
[16] J. I. Cleeman, “Executive summary of the third report of
the National Cholesterol Education Program (NCEP) expert
panel on detection, evaluation, and treatment of high blood
cholesterol in adults (adult treatment panel III),” Journal of the
American Medical Association, vol. 285, no. 19, pp. 2486–2497,
2001.
[17] H. J. Milionis, E. N. Liberopoulos, M. S. Elisaf, and D. P.
Mikhailidis, “Analysis of antihypertensive eﬀects of statins,”
Current Hypertension Reports, vol. 9, no. 3, pp. 175–183, 2007.
[18] H. J. Milionis, E. N. Liberopoulos, A. Achimastos, M. S. Elisaf,
and D. P. Mikhailidis, “Statins: another class of antihyperten-
siveagents?”JournalofHumanHypertension,v ol.20,no .5,pp .
320–335, 2006.
[19] E. Reisin, P. J. Ebenezer, J. Liao et al., “Eﬀect of the HMG-Coa
reductaseinhibitorrosuvastatinonearlychronickidneyinjury
in obese zucker rats fed with an atherogenic diet,” American
Journal of the Medical Sciences, vol. 338, no. 4, pp. 301–309,
2009.
[20] M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf, “Current
role of statins in the treatment of essential hypertension,”
Expert Opinion on Pharmacotherapy, vol. 11, no. 16, pp. 2635–
2650, 2010.
[21] A. C. Barreto, N. Y. Maeda, R. P. S. Soares, C. C´ ıcero, and A.
A. Lopes, “Rosuvastatin and vascular dysfunction markers in
pulmonary arterial hypertension: a placebo-controlled study,”
Brazilian Journal of Medical and Biological Research, vol. 41,
no. 8, pp. 657–663, 2008.
[22] B. Yavuz, D. T. Ertugrul, H. Cil et al., “Increased levels
of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after
rosuvastatin treatment: a novel pleiotropic eﬀect of statins?”
Cardiovascular Drugs and Therapy, vol. 23, no. 4, pp. 295–299,
2009.
[23] M. Florentin, M. S. Elisaf, D. P. Mikhailidis et al., “Vitamin D
and metabolic syndrome: is there a link?” Current Pharmaceu-
tical Design, vol. 16, pp. 3417–3434, 2010.
[24] M. Florentin, E. N. Liberopoulos, A. A. Kei, D. P. Mikhailidis,
and M. S. Elisaf, “Pleiotropic eﬀects of nicotinic acid: beyond
High Density Lipoprotein Cholesterol elevation,” Current
Vascular Pharmacology. In press.
[25] A. A. Kei, E. N. Liberopoulos, and M. S. Elisaf, “What restricts
nicotinic acid’s clinical use?” Current Vascular Pharmacology.
In press.
[26] C. A. Gadegbeku, A. Dhandayuthapani, M. Z. Shrayyef, and B.
M. Egan, “Hemodynamic eﬀects of nicotinic acid infusion in
normotensive and hypertensive subjects,” American Journal of
Hypertension, vol. 16, no. 1, pp. 67–71, 2003.
[27] J. J. Kelly, J. A. Lawson, L. V. Campbell et al., “Eﬀects of
nicotinic acid on insulin sensitivity and blood pressure in
healthy subjects,” Journal of Human Hypertension, vol. 14, no.
9, pp. 567–572, 2000.
[28] P. L. Canner, C. D. Furberg, and M. E. McGovern, “Beneﬁts of
niacininpatientswithversuswithoutthemetabolicsyndrome
and healed myocardial infarction (from the Coronary Drug
Project),” American Journal of Cardiology,v o l .9 7 ,n o .4 ,p p .
477–479, 2006.
[29] J. F. Paolini, Y. B. Mitchel, R. Reyes et al., “Eﬀects of
laropiprantonnicotinicacid-inducedﬂushinginpatientswith
dyslipidemia,” American Journal of Cardiology, vol. 101, no. 5,
pp. 625–630, 2008.
[30] K.G.Parhofer,“Reviewofextended-releaseniacin/laropiprant
ﬁxed combination in the treatment of mixed dyslipidemia
and primary hypercholesterolemia,” Vascular Health and Risk
Management, vol. 5, pp. 901–908, 2009.
[31] M. Florentin, E. N. Liberopoulos, A. S. Wierzbicki, and D.
P. Mikhailidis, “Multiple actions of high-density lipoprotein,”
Current Opinion in Cardiology, vol. 23, no. 4, pp. 370–378,
2008.
[32] S. A. Sorrentino, C. Besler, L. Rohrer et al., “Endothelial-
vasoprotective eﬀects of high-density lipoprotein are impaired
inpatientswithtype2diabetesmellitusbutareimprovedafter
extended-release niacin therapy,” Circulation, vol. 121, no. 1,
pp. 110–122, 2010.
[33] J. P. Cooke, “Asymmetrical dimethylarginine: the ¨ Uber
marker?” Circulation, vol. 109, no. 15, pp. 1813–1819, 2004.
[34] S. Westphal, K. Borucki, C. Luley, J. Martens-Lobenhoﬀer, and
S. M. Bode-B¨ oger, “Treatment with niacin lowers ADMA,”
Atherosclerosis, vol. 184, no. 2, pp. 448–450, 2006.